
Acquired Hemophilia is an autoimmune disorder which attacks blood clotting factor VIII, thus, obstructing its purpose. It is not widely recognized because it is so rare, as the majority of hemophilia cases are diagnosed early in childhood and are genetic. Unlike most hemophilia, which is most common in males, acquired hemophilia affects both men and women the same.
Also Read - What Is Acquired Hemophilia?
HbAs is a sickle cell trait, where the patient has one normal gene from the parent and one abnormal gene. Sickle cell disease is a genetic disorder of which the red blood cells in a patients blood are sticky and hard when exposed to low oxygen, causing blockages and constant shortages of red blood cells. It is extremely rare to have both hemophilia and a sickle cell trait (HbAs).
Also Read - Sickle Cell and Hemophilia?
In the Cureus Journal of Medical Science, a recent article published by Syed Hamza Bin Waqar, Leen Khoury, Ather Hussain, and Isabel M McFarlane, focuses on hemophilia A being acquired during the peripartum period in a patient with sickle cell trait. This is extremely rare to have both acquired hemophilia A and sickle cell trait.
The report describes a 31-year-old woman's delivery of a healthy baby via cesarean section, where the woman developed acquired hemophilia A. According to the report, the woman "developed injection-site hematoma over the triceps and the site of the incision. She also had an episode of profuse bleeding from intravenous lines placed." She then undergone transfusions of fresh frozen plasma units, four over a few hours. The bleeding continued. Her hemoglobin level decreased from her baseline by 4.5 g/dL and eventually was given, and completed, a course of rituximab. Her latest update, as per the report, is that she is managed at a hematology clinic after her 2-week follow up showed progress. You can read the full study here.
Want to learn more about bleeding disorders? Sign up for our newsletter here! SIGN UP
Comentários